Aprea Therapeutics, Inc. (APRE)
0.538
+0.02
(+4.87%)
USD |
NASDAQ |
Oct 28, 16:00
0.538
0.00 (0.00%)
After-Hours: 18:44
Aprea Therapeutics Enterprise Value : -34.15M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | -34.15M |
| October 26, 2026 | -34.94M |
| October 23, 2026 | -34.09M |
| October 22, 2026 | -33.80M |
| October 21, 2026 | -33.56M |
| October 20, 2026 | -33.55M |
| October 19, 2026 | -33.91M |
| October 16, 2026 | -33.27M |
| October 15, 2026 | -32.85M |
| October 14, 2026 | -33.28M |
| October 13, 2026 | -33.07M |
| October 12, 2026 | -33.16M |
| October 09, 2026 | -33.02M |
| October 08, 2026 | -33.59M |
| October 07, 2026 | -33.01M |
| October 06, 2026 | -32.63M |
| October 05, 2026 | -32.13M |
| October 02, 2026 | -31.89M |
| October 01, 2026 | -31.54M |
| September 30, 2026 | -31.21M |
| September 29, 2026 | -30.97M |
| September 28, 2026 | -31.19M |
| September 25, 2026 | -31.08M |
| September 24, 2026 | -30.84M |
| September 23, 2026 | -30.84M |
| Date | Value |
|---|---|
| September 22, 2026 | -31.43M |
| September 21, 2026 | -31.37M |
| September 18, 2026 | -31.09M |
| September 17, 2026 | -31.21M |
| September 16, 2026 | -31.45M |
| September 15, 2026 | -31.23M |
| September 14, 2026 | -30.82M |
| September 11, 2026 | -30.92M |
| September 10, 2026 | -30.73M |
| September 09, 2026 | -30.70M |
| September 08, 2026 | -30.16M |
| September 04, 2026 | -30.66M |
| September 03, 2026 | -30.52M |
| September 02, 2026 | -30.35M |
| September 01, 2026 | -30.15M |
| August 31, 2026 | -30.59M |
| August 28, 2026 | -30.11M |
| August 27, 2026 | -29.85M |
| August 26, 2026 | -28.36M |
| August 25, 2026 | -28.74M |
| August 24, 2026 | -30.53M |
| August 21, 2026 | -32.57M |
| August 20, 2026 | -32.58M |
| August 19, 2026 | -32.19M |
| August 18, 2026 | -32.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zymeworks, Inc. | 2.074B |
| Rhythm Pharmaceuticals, Inc. | 6.237B |
| ACADIA Pharmaceuticals, Inc. | 2.589B |
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| Anika Therapeutics, Inc. | 272.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.591M |
| Total Expenses (Quarterly) | 3.591M |
| EPS Diluted (Quarterly) | -0.0671 |
| Earnings Yield | -200.1% |
| Normalized Earnings Yield | -200.17 |